 |
| What is Type 1 diabetes? | What is the AIDA study? | How to Join | Clinical Centers and Locations | Contact Us | Home |
Administrative concerns or questions about AIDA can be addressed to:
Annette Thyde
Study Administrator
+45 4443 9383
AIDA Coordinating Center
Steno Diabetes Center
Department of Translational Diabetology
2 Niels Steensensvej
2820 Gentofte
Denmark
 |
What is  |
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1 diabetes. The study employs a randomized, placebo-controlled, double-masked, parallel-group, multi-centre design. Participating clinical centres are located in 11 countries throughout Europe. |
Supported by: The active drug (Kineret®) and the non active “dummy” drug are provided by Amgen. Amgen does not provide funding for the conduct of the trial or to the researchers. The expenses of the trial are funded by grants from Juvenile Diabetes Foundation International, New York, USA, the world’s largest private diabetes fund. Funding also provided by Oresund Diabetes Academy and Steno Diabetes Center, Denmark. |
| Site Map | Contact Us | AIDA Locations | Accessibility | Contact the Web Master | AIDA Member Web Site | |
